Question 1

What is SUL-238?

Accepted Answer

SUL-238 is a Other.

Question 2

How often does SUL-238 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was SUL-238 first tracked by Ergen?

Accepted Answer

First tracked on Jun 08, 2026.

Question 4

When was SUL-238 last mentioned in news?

Accepted Answer

Last active on Jun 08, 2026.

Question 5

What is SUL-238's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is SUL-238 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving SUL-238?

Accepted Answer

GEN Doses First Patient SUL-238 (Jun 08, 2026, 6 articles).

Question 8

How did the "GEN Doses First Patient SUL-238" event impact SUL-238?

Accepted Answer

SUL-238 is the novel small molecule drug being tested in the Phase II clinical trial for Parkinson s disease, with potential to be a transformative treatment.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.